Lytix Biopharma: Presentation of fourth quarter 2021 results, Thursday 17 February

10 Feb 2022 09:22 CET

Lytix Biopharma AS will release its fourth quarter 2021 results on Thursday, 17
February at 7 am CEST. The results will be presented in a webcast with CEO
Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30 pm CEST.

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here:
https://forms.office.com/pages/responsepage.aspx?id=-QEn0CM7P0uPzintVGMr-Gxc6nJw
_YlNh1teJiuU8DNURjBZTFpOUExYVklTTk9GM0hXM09ZV09ZOC4u

A recording of the presentation will after the presentation be made available on
https://www.lytixbiopharma.com/investors/overview.html


For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512


Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical stage
biotech company developing novel cancer immunotherapies, an area within cancer
therapy that is aimed at activating the patient’s immune system to fight cancer.
The Company’s technology is based on pioneering research in “host defense
peptides” – nature’s first line of defense towards foreign pathogens. Lytix
Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule
representing a new and superior in situ therapeutic vaccination principle to
boost anti-cancer immunity, with the potential to be the ideal combination
partner with other types of immunotherapy. LTX-315 target cancer cells and
disintegrate their cell membranes, causing immunogenic cell death and release of
a patient’s tumor specific antigens. This mode of action allows cytotoxic T
cells to recognize, infiltrate, and attack cancer cells. The Company was listed
on Euronext Growth in Oslo in June 2021, following a private placement covered
by investors such as PBM Capital, a US based, healthcare-focused investment
firm.

More information:
Access the news on Oslo Bors NewsWeb site